Skip to main content
SpringerLink
Log in

Comparative Tolerability of Pharmacological Treatments for Patent Ductus Arteriosus

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

The ductus arteriosus is a vascular channel which, although vital to the fetal circulation, rapidly becomes unnecessary and even deleterious after birth. As such, it is ‘preprogrammed’ to constrict within the first few hours of life. In infants born prematurely this natural closure is often delayed and/or ineffective. In this review, we summarise the current knowledge of the delicately orchestrated control of normal ductal closure, with emphasis on the role of various biochemical mediators.

The major focus of this review, however, is on pharmacological approaches designed to prevent and/or treat the persistently patent ductus arteriosus (PDA) which often fails to constrict spontaneously in the premature infant. The standard treatment regimen is based on the administration of 3 doses of the nonselective cyclo-oxygenase inhibitor, indomethacin. We begin by examining, from the vantage point of the ductus, the use of this indomethacin as a tocolytic. It seems that antenatal administration of indomethacin can cause transient, reversible ductus constriction which renders the post-treatment ductus resistant to subsequent closure, both natural and therapeutic. We then review some of the pros and cons associated with the prophylactic administration of indomethacin. Although prophylactic indomethacin is aimed primarily at preventing intraventricular haemorrhages in premature neonates, it does tend to reduce the risk of PDA as well.

We then describe some novel therapeutic approaches to effect ductal closure with indomethacin, including the use of continuous infusions to minimise toxic vasoconstrictive phenomena and the use of prolonged maintenance dose to prevent PDA recurrences.

Finally we discuss some of the newer agents described more recently which play a role in closing the persistently patent ductus over the next decade. Most prominent of these is ibuprofen which some studies have shown to have less undesirable vasoconstrictive adverse effects. Studies which compare the use of ibuprofen to indomethacin are summarised.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II

Similar content being viewed by others

References

  1. Ellison R, Peckham G, Lang P, et al. Evaluation of the preterm infant for patent ductus arteriosus. Pediatrics 1983; 71: 364–72

    PubMed  CAS  Google Scholar 

  2. Emmanouilides G. Persistent patency of the ductus arteriosus in premature infants: incidence, perinatal factors and natural history. In: Heymann M, Rudolph A, editors. The ductus arteriosus: the 75th Ross Conference on Pediatric Research. Columbus (OH): Ross Laboratories, 1978: 63–9

    Google Scholar 

  3. Noel S, Cassin S. Maturation of contractile response of ductus arteriosus to oxygen and drugs. Am J Physiol 1976; 231: 240–3

    PubMed  CAS  Google Scholar 

  4. Rabinovitch M, Boudreau N, Vella G, et al. Oxygen related prostaglandin synthesis in ductus arteriosus and other vascular cells. Pediatr Res 1989; 26: 330–5

    Article  PubMed  CAS  Google Scholar 

  5. McMurphy DM, Heymann MA, Rudolph AM, et al. Developmental changes in constriction of the ductus arteriosus: responses to oxygen and vasoactive substances in the isolated ductus arteriosus of the fetal lamb. Pediatr Res 1972; 6: 231–8

    Article  PubMed  CAS  Google Scholar 

  6. Clyman RI. Ontogeny of the ductus arteriosus response to prostaglandins and inhibitors of their synthesis. Semin Perinatol 1980; 4: 115–24

    PubMed  CAS  Google Scholar 

  7. Hammerman C, Aramburo MJ. Effects of hyperventilation on prostacyclin formation and on pulmonary vasodilation after GBS induced pulmonary hypertension. Pediatr Res 1991; 29: 282–7

    Article  PubMed  CAS  Google Scholar 

  8. Hammerman C, Zangen D. Indomethacin and apnea of prematurity. Critical Care Med 1993; 21: 154–5

    Article  CAS  Google Scholar 

  9. Gonzalez A, Sosenko IR, Chandar J, et al. Incidence of infection on patent ductus arteriosus and chronic lung disease in premature infants weighing 1000 grams or less. J Pediatr 1996; 128: 470–8

    Article  PubMed  CAS  Google Scholar 

  10. Clyman RI, Waleh N, Black SM, et al. Regulation of ductus arteriosus patency by nitric oxide in fetal lambs: the role of gestation, oxygen tension and vasavasorum. Pediatr Res 1998; 43: 633–44

    Article  PubMed  CAS  Google Scholar 

  11. Zuckerman H, Reiss U, Rubinstein I. Inhibition of human premature labor by indomethacin. Obstet Gynecol 1974; 44: 782–92

    Google Scholar 

  12. Arcilla R, Thilenius O, Ranniger K. Congestive heart failure from suspected ductal closure in utero. J Pediatr 1969; 75: 74–8

    Article  PubMed  CAS  Google Scholar 

  13. Momma K, Konishi T, Hagiwara H. Characteristic morphology of the constricted fetal ductus arteriosus following maternal administration of indomethacin. Pediatr Res 1985; 19: 493–500

    Article  PubMed  CAS  Google Scholar 

  14. Levin DL, Mills LJ, Parkey M, et al. Constriction of the fetal ductus arteriosus after administration of indomethacin to the pregnant ewe. J Pediatr 1979; 94: 647–50

    Article  PubMed  CAS  Google Scholar 

  15. Olley PM, Bodach E, Heaton J, et al. Further evidence implicating E-type prostaglandins in the patency of the lamb ductus arteriosus. Eur J Pharmacol 1975; 34: 247–50

    Article  PubMed  CAS  Google Scholar 

  16. Fay FS. Guinea pig ductus arteriosus. I. Cellular and metabolic basis for oxygen sensitivity. Am J Physiol 1971; 221: 470–9

    PubMed  CAS  Google Scholar 

  17. Csaba IF, Sulyok E, Ertl T. Clinical note: relationship of maternal treatment with indomethacin to persistence of fetal circulation syndrome. J Pediatr 1978; 92: 484–8

    Article  PubMed  CAS  Google Scholar 

  18. Van den Veyver IB, Moise Jr KJ, Ou CN, et al. The effect of gestational age and fetal indomethacin levels on the incidence of constriction of the fetal ductus arteriosus. Obstet Gynecol 1993; 82: 500–3

    PubMed  Google Scholar 

  19. Vermillion ST, Scardo JA, Lashus AG, et al. The effect of indomethacin tocolysis on fetal ductus arteriosus constriction with advancing gestational age. Am J Obstet Gynecol 1997; 177: 256–9

    Article  PubMed  CAS  Google Scholar 

  20. Moise KJ, Huhta J, Sharif D, et al. Indomethacin in the treatment of premature labor N Engl J Med 1988; 319: 327–31

    Google Scholar 

  21. Manchester D, Margolis HS, Sheldon RE. Possible association between maternal indomethacin therapy and primary pulmonary hypertension of the newborn. Am J Obstet Gynecol 1976; 126: 467–9

    PubMed  CAS  Google Scholar 

  22. Norton M, Merrill J, Cooper B, et al. Neonatal Complications after the administration of indomethacin for preterm labor. N Engl J Med 1993; 329: 1602–7

    Article  PubMed  CAS  Google Scholar 

  23. Bandstra E, Montalvo B, Goldberg R, et al. Prophylactic indomethacin for prevention of intraventricular hemorrhage in premature infants. Pediatrics 1988; 82: 533–42

    PubMed  CAS  Google Scholar 

  24. Souter D, Harding J, McCowan L, et al. Antenatal indomethacin - adverse fetal effects confirmed. Aust N Z J Obstet Gynaecol 1998; 38: 11–6

    Article  PubMed  CAS  Google Scholar 

  25. Hammerman C, Glaser J, Kaplan M, et al. Indomethacin tocolysis impairs postnatal postnatal patent ductus arteriosus severity. Pediatrics 1998; 102: E56–9

    Article  PubMed  CAS  Google Scholar 

  26. Gittenberger-de Groot AC, van Ertbruggen I, Moulaert AJ, et al. The ductus arteriosus: histological and clinical observations. J Pediatr 1980; 96: 88–93

    Article  PubMed  CAS  Google Scholar 

  27. Benjamin DR, Wiegenstein L. Necrosis of the ductus arteriosus in premature infants. Arch Pathol 1972; 94: 340–2

    PubMed  CAS  Google Scholar 

  28. Ibara S, Tokunaga M, Ikenous T, et al. Histologic observation of the ductus arteriosus in premature infants with intrauterine growth retardation. J Perinatol 1994; 14: 411–6

    PubMed  CAS  Google Scholar 

  29. Ment LR, Duncan CC, Ehrenkranz RA, et al. Randomized low dose indomethacin trial for prevention of intraventricular hemorrhage in very low birthweight neonates. J Pediatr 1988; 112: 948–55

    Article  PubMed  CAS  Google Scholar 

  30. Couser RJ, Hoekstra RE, Ferrara TB, et al. Neurodevelopmental follow-up at 36 months’ corrected age of preterm infants treated with prophylactic indomethacin. Arch Pediatr Adolesc Med 2000; 154: 598–602

    PubMed  CAS  Google Scholar 

  31. Ment LR, Vohr B, Allan W, et al. Outcome of children in the indomethacin intraventricular hemorrhage prevention trial. Pediatrics 2000; 105: 485–91

    Article  PubMed  CAS  Google Scholar 

  32. Couser RJ, Ferrara TB, Wright GB, et al. Prophylactic indomethacin therapy in the first twenty-four hours of life for the prevention of patent ductus arteriosus in preterm infants treated prophylactically with surfactant in the delivery room. J Pediatr 1996; 128: 631–7

    Article  PubMed  CAS  Google Scholar 

  33. Narayanan M, Cooper B, Weiss H, et al. Prophylactic indomethacin: factors determining permanent ductus arteriosus closure. J Pediatr 2000; 136: 330–7

    Article  PubMed  CAS  Google Scholar 

  34. Kaapa P, Lanning P, Koivisto M. Early closure of patent ductus arteriosus with indomethacin in preterm infants with idiopathic respiratory distress syndrome. Acta Paediatr Scand 1983; 72: 179–84

    Article  PubMed  CAS  Google Scholar 

  35. Ment LR, Oh W, Ehrenkranz RA, et al. Low-dose indomethacin therapy and extension of intraventricular hemorrhage: a multicenter randomized trial. J Pediatr 1994; 124: 951–5

    Article  PubMed  CAS  Google Scholar 

  36. Vincer M, Allen A, Evans J, et al. Early intravenous indomethacin prolongs respiratory support in very low birth weight infants. Acta Paediatr Scand 1987; 76: 894–7

    Article  PubMed  CAS  Google Scholar 

  37. Mardoum R, Bejar R, Merritt A, et al. Controlled study of the effects of indomethacin on cerebral blood flow velocities in newborn infants. J Pediatr 1991; 118: 112–5

    Article  PubMed  CAS  Google Scholar 

  38. Fowlie PW. Prophylactic indomethacin: systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed 1996 Mar; 74(2): F81–7

    Article  PubMed  CAS  Google Scholar 

  39. Fowlie PW. Intravenous indomethacin for preventing mortality and morbidity in very low birth weight in infants (Cochrane Review). In: The Cochrane Library; issue 2, Oxford: Update Software 2001

    Google Scholar 

  40. Yanowitz TD, Yao AC, Werner JC, et al. Effects of prophylactic low-dose indomethacin on hemodynamics in very low birth weight infants. J Pediatr 1998; 132: 28–34

    Article  PubMed  CAS  Google Scholar 

  41. Hammerman C, Strates E, Komar K, et al. Failure of prophylactic indomethacin to improve the outcome of the very low birth weight infant. Dev Pharmacol Ther 1987; 10: 393–404

    PubMed  CAS  Google Scholar 

  42. Fowlie PW. Intravenous indomethacin for preventing mortality andmorbidity in very low birth weight infants. In: The Cochrane Library; CD000174. Oxford: Update Software, 2000

    Google Scholar 

  43. Ment LR, Oh W, Ehrenkranz RA, et al. Low-dose indomethacin therapy and extension of intraventricular hemmorhage: a multicenter randomized trial. J Pediatr 1994 Jun; 124: 951–5

    Article  PubMed  CAS  Google Scholar 

  44. Corazza MS, Davis RF, Merritt TA, et al. Prolonged bleeding time in preterm infants receiving indomethacin for patent ductus arteriosus. J Pediatr 1984 Aug; 105: 292–6

    Article  PubMed  CAS  Google Scholar 

  45. Su BH, Peng CT, Tsai CH. Echocardiographic flow pattern of patent ductus arteriosus: a guide to indomethacin treatment in premature infants. Arch Dis Child Fetal Neonatal Ed 1999; 81: F197–200

    Article  PubMed  CAS  Google Scholar 

  46. Tammela O, Ojala R, Iivainen T, et al. Short vs. prolonged indomethacin therapy for patent ductus arteriosus in preterm infants. J Pediatr 1999; 134: 552–7

    Article  PubMed  CAS  Google Scholar 

  47. Rhodes PG, Ferguson MG, Reddy NS, et al. Effects of prolonged versus acute indomethacin therapy in very low birth weight infants with patent ductus arteriosus. Eur J Pediatr 1988; 147: 481–4

    Article  PubMed  CAS  Google Scholar 

  48. Rennie JM, Cooke RW. Prolonged low dose indomethacin for persistent ductus arteriosus of prematurity. Arch Dis Child 1991; 66: 55–8

    Article  PubMed  CAS  Google Scholar 

  49. Hammerman C, Glaser J, Schimmel MS, et al. Continuous vs. multiple rapid infusions of indomethacin: effects on cerebral blood flow velocity. Pediatrics 1995; 95: 244–8

    PubMed  CAS  Google Scholar 

  50. Clyman RI. Patent ductus arteriosus in the premature infant. In: Taeusch HW, Ballard RR, editors. Avery’s diseases of the newborn. Philadelphia (PA): W.B. Saunders, 1998: 699–717

    Google Scholar 

  51. Laudignon N, Chemtob S, Bard H, et al. Effect of indomethacin on cerebral blood flow velocity of premature newborns. Biol Neonate 1988; 54: 254–82

    Article  PubMed  CAS  Google Scholar 

  52. Pryds O, Greisen G, Johansen K. Indomethacin and cerebral blood flow in premature infants treated for patent ductus arteriosus. Eur J Pediatr 1988; 147: 315–6

    Article  PubMed  CAS  Google Scholar 

  53. Edwards A, Wyatt J, Richardson C, et al. Effects of indomethacin of cerebral hemodynamics in very preterm infants. Lancet 1990; 335: 1491–5

    Article  PubMed  CAS  Google Scholar 

  54. Van Bel F, Van De Bor M, Stijnen T, et al. Cerebral blood flow velocity changes in preterm infants after a single dose of indomethacin: duration of its effects. Pediatrics 1989; 84: 802–7

    PubMed  Google Scholar 

  55. Evans D, Levene M, Archer L. The effect of indomethacin on cerebral blood flow velocity in premature infants. Dev Med Child Neurol 1987; 29: 776–82

    Article  PubMed  CAS  Google Scholar 

  56. Van Bel F, Klautz R, Steendijk P, et al. The influence of indomethacin on the autoregulatory ability of the cerebral vascular bed in the newborn lamb. Pediatr Res 1993; 34: 178–81

    Article  PubMed  Google Scholar 

  57. Leffler CW, Busija DW, Beasley DG, et al. Maintenance of cerebral circulation during hemorrhagic hypotension in newborn pigs. Circ Res 1986; 59: 562–7

    Article  PubMed  CAS  Google Scholar 

  58. Austin NC, Pairaudeau PW, Hames TK, et al. Regional cerebral blood flow velocity changes after indomethacin infusion in premature infants. Arch Dis Child 1992; 67: 851–4

    Article  PubMed  CAS  Google Scholar 

  59. Colditz P, Murphy D, Rolfe P, et al. Effect of infusion rate of indomethacin on cerebrovascular responses in preterm neonates. Arch Dis Child 1989; 64: 8–12

    Article  PubMed  CAS  Google Scholar 

  60. Simko A, Mardoum R, Merritt TA, et al. Effects on cerebral blood flow velocities of slow and rapid infusion of indomethacin. J Perinatol 1994; 14: 29–35

    PubMed  CAS  Google Scholar 

  61. Mellander M, Leheup B, Lindstrom DP, et al. Recurrence of symptomatic patent ductus arteriosus in extremely premature infants treated with indomethacin. J Pediatr 1984; 105: 138–43

    Article  PubMed  CAS  Google Scholar 

  62. Seyberth H, Muller H, Wille L, et al. Recovery of prostaglandin reopening of the ductus arteriosus after indomethacin treatment in preterm infants with respiratory distress syndrome. Pediatr Pharmacol 1982; 2: 127–41

    CAS  Google Scholar 

  63. Clyman RI, Campbell D, Heymann MA, et al. Persistent responsiveness of the neonatal ductus arteriosus in immature lambs: a possible cause for reopening of patent ductus arteriosus after indomethacin induced closure. Circulation 1985; 71: 141–5

    Article  PubMed  CAS  Google Scholar 

  64. Hammerman C, Aramburo MJ. Prolonged indomethacin therapy for the prevention of recurrences of patent ductus arteriosus. J Pediatr 1990; 117: 771–6

    Article  PubMed  CAS  Google Scholar 

  65. Seyberth HW, Rascher W, Hackenthal R, et al. Effect of prolonged indomethacin therapy on renal function and selected vasoactive hormones in very-low-birth-weight infants with symptomatic patent ductus arteriosus. J Pediatr 1983; 103: 979–84

    Article  PubMed  CAS  Google Scholar 

  66. Green TP, Thompson TR, Johnson DE, et al. Furosemide promotes patent ductus arteriosus in premature infants with the respiratory-distress syndrome. N Engl J Med 1983; 308: 743–8

    Article  PubMed  CAS  Google Scholar 

  67. Brion LP, Campbell DE. Furosemide for symptomatic patent ductus arteriosus in indomethacin-treated infants. In: The Cochrane Library; CD001148. Oxford: Update Software, 2000

    Google Scholar 

  68. Seri I, Tulassay T, Kiszel J, et al. The use of dopamine for the prevention of the renal side effects of indomethacin in premature infants with patent ductus arteriosus. Int J Pediatr Nephrol 1984; 5: 209–14

    PubMed  CAS  Google Scholar 

  69. Fajardo CA, Whyte RK, Steele BT. Effect of dopamine on failure of indomethacin to close the patent ductus arteriosus. J Pediatr 1992; 121: 771–5

    Article  PubMed  CAS  Google Scholar 

  70. Baenziger O, Waldvogel K, Ghelfi D, et al. Can dopamine prevent the renal side effects of indomethacin? A prospective randomized clinical study. Klin Padiatr 1999; 211: 438–41

    Article  PubMed  CAS  Google Scholar 

  71. Simons L, Mills J. Nonsteroidal anti-inflammatory drugs, N Engl J Med 1980; 302: 1237–43

    Article  Google Scholar 

  72. Sakhalkar VS, Merchant RH. Therapy of symptomatic patent ductus arteriosus in preterms using mefenemic acid and indomethacin. Indian Pediatr 1992; 29: 313–8

    PubMed  CAS  Google Scholar 

  73. Varvarigou N, Bardin CL, Beharry K, et al. Early ibuprofen administration to prevent patent ductus arteriosus in premature infants. JAMA 1996; 275: 539–44

    Article  PubMed  CAS  Google Scholar 

  74. SoRelle R. Ibuprofen as effective as indomethacin for patent ductus arteriosus. Circulation 2000; 102: E9007–8

    Article  PubMed  CAS  Google Scholar 

  75. Van Overmeire B, Smets K, Lecoutere D, et al. A Comparison of ibuprofen and indomethacin for closure of patent ductus arteriosus. N Engl J Med 2000; 343: 674–81

    Article  PubMed  Google Scholar 

  76. Van Overmeire B, Follens I, Hartmann S, et al. Treatment of patent ductus arteriosus with ibuprofen. Arch Dis Child Fetal Neonatal Ed 1997; 76: F179–84

    Article  PubMed  Google Scholar 

  77. Pezzati M, Vangi V, Biagiotti R, et al. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr 1999; 135: 733–8

    Article  PubMed  CAS  Google Scholar 

  78. Feigen LP, King LW, Ray J, et al. Differential effects of ibuprofen and indomethacin in the regional circulation of the dog. Pharmacol Exp Ther 1981; 219: 679–84

    CAS  Google Scholar 

  79. Grosfeld JL, Kamman K, Gross K, et al. Comparative effects of indomethacin, prostaglandin E1, and ibuprofen on bowel ischemia. J Pediatr Surg 1983; 18: 738–42

    Article  PubMed  CAS  Google Scholar 

  80. Speziale MV, Allen RG, Henderson CR, et al. Effects of ibuprofen and indomethacin on the regional circulation in newborn piglets. Biol Neonate 1999; 76: 242–52

    Article  PubMed  CAS  Google Scholar 

  81. Chamaa NS, Mosig D, Drukker A, et al. The renal hemodynamic effects of ibuprofen in the newborn rabbit. Pediatr Res 2000; 48: 600–5

    Article  PubMed  CAS  Google Scholar 

  82. Patel J, Roberts I, Azzopardi D, et al. Randomized double-blind controlled trial comparing the effects of ibuprofen with indomethacin on cerebral hemodynamics in preterm infants with patent ductus arteriosus. Pediatr Res 2000; 47: 36–42

    Article  PubMed  CAS  Google Scholar 

  83. Mosca F, Bray M, Lattanzio M, et al. Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. J Pediatr 1997; 131: 549–54

    Article  PubMed  CAS  Google Scholar 

  84. Aranda JV, Parker J, Glibetic M, et al. Comparative dose response effects of ibuprofen and indomethacin on prostaglandin E2, PGE2 synthesis in neonatal cerebral microvessels [abstract]. Pediatr Res 1998; 43: 58A

    Article  Google Scholar 

  85. Cooper-Peel C, Brodersen R, Robertson A. Does ibuprofen affect bilirubin-albumin binding in newborn infant serum? Pharmacol Toxicol 1996; 79: 297–9

    Article  PubMed  CAS  Google Scholar 

  86. Brodersen R, Ebbesen F. Bilirubin-displacing effect of ampicillin, indomethacin, newborn infants. J Pharm Sci 1983; 72: 248–53

    Article  PubMed  CAS  Google Scholar 

  87. Clyman RI. Ibuprofen and the patent ductus. N Engl J Med 2000; 343: 728–30

    Article  PubMed  CAS  Google Scholar 

  88. DeCarolis MP, Romagnoli C, Polimeni V, et al. Prophylactic ibuprofen therapy of patent ductus arteriosus in preterm infants. Eur J Pediatr 2000; 159: 364–8

    Article  CAS  Google Scholar 

  89. Romagnoli C, DeCarolis MP, Papaddi P, et al. Effects of prophylactic ibuprofen on cerebral and renal hemodynamics in very preterm neonates. Clin Pharmacol Ther 2000; 67: 676–83

    Article  PubMed  CAS  Google Scholar 

  90. Clyman RI, Hardy P, Waleh N, et al. Cyclooxygenase-2 plays a significant role in regulating the tone of the fetal lamb ductus arteriosus. Am J Physiol 1999; 276: R913–21

    PubMed  CAS  Google Scholar 

  91. Guerguerian AM, Hardy P, Bhattacharya M, et al. Expression of cyclooxygenases in ductus arteriosus of fetal and newborn pigs. Am J Obstet Gynecol 1998; 179: 1618–26

    Article  PubMed  CAS  Google Scholar 

  92. Smith GC. The pharmacology of the ductus arteriosus. Pharmacol Rev 1998; 50: 35–58

    PubMed  CAS  Google Scholar 

  93. Bhattacharya M, Asselin P, Hardy P, et al. Developmental changes in prostaglandin E2 receptor subtypes in porcine ductus arteriosus: possible contribution in altered responsiveness to prostaglandin E2. Circulation 1999; 100: 1751–6

    Article  PubMed  CAS  Google Scholar 

  94. Clyman RI, Seidner S, Koch C. Combined prostaglandin and nitric oxide inhibition facilitates permanent closure of the PDA in premature baboons. Pediatr Res. In press

Download references

Author information

Authors and Affiliations

  1. Department of Neonatology, Shaare Zedek Medical Center, POB 3235, Jerusalem, 91031, Israel

    Cathy Hammerman & Michael Kaplan

Authors
  1. Cathy Hammerman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael Kaplan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Cathy Hammerman.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hammerman, C., Kaplan, M. Comparative Tolerability of Pharmacological Treatments for Patent Ductus Arteriosus. Drug-Safety 24, 537–551 (2001). https://doi.org/10.2165/00002018-200124070-00005

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200124070-00005

Keywords

Search

Navigation